Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Long-Term Debt Repayments (2020)

10x Genomics' Long-Term Debt Repayments history spans 1 years, with the latest figure at $31.3 million for Q1 2020.

  • For Q1 2020, Long-Term Debt Repayments changed N/A year-over-year to $31.3 million; the TTM value through Dec 2020 reached $31.3 million, changed N/A, while the annual FY2020 figure was $31.3 million, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q1 2020 was $31.3 million at 10x Genomics.
  • Across five years, Long-Term Debt Repayments topped out at $31.3 million in Q1 2020 and bottomed at $31.3 million in Q1 2020.